Targeted Delivery of Macrophage Membrane Biomimetic Liposomes Through Intranasal Administration for Treatment of Ischemic Stroke
Tianshu Liu,Mengfan Zhang,Jin Zhang,Naijin Kang,Linlin Zheng,Zhiying Ding
DOI: https://doi.org/10.2147/ijn.s458656
IF: 7.033
2024-06-20
International Journal of Nanomedicine
Abstract:Tianshu Liu, Mengfan Zhang, Jin Zhang, Naijin Kang, Linlin Zheng, Zhiying Ding School of Pharmaceutical Sciences, Jilin University, Changchun, 130021, People's Republic of China Correspondence: Zhiying Ding, School of Pharmaceutical Sciences, Jilin University, Changchun, 130021, People's Republic of China, Tel/Fax +86 13843180286, Email Purpose: Ginsenoside Rg3 (Rg3) and Panax notoginseng saponins (PNS) can be used for ischemic stroke treatment, however, the lack of targeting to the ischemic region limits the therapeutic effect. To address this, we leveraged the affinity of macrophage membrane proteins for inflamed brain microvascular endothelial cells to develop a macrophage membrane-cloaked liposome loaded with Rg3 and PNS (MM-Lip-Rg3/PNS), which can precisely target brain lesion region through intranasal administration. Methods: MM-Lip-Rg3/PNS was prepared by co-extrusion method and was performed by characterization, stability, surface protein, and morphology. The cellular uptake, immune escape ability, and blood-brain barrier crossing ability of MM-Lip-Rg3/PNS were studied in vitro. The in vivo brain targeting, biodistribution and anti-ischemic efficacy of MM-Lip-Rg3/PNS were evaluated in MACO rats, and we determined the diversity of the nasal brain pathway through the olfactory nerve blockade model in rats. Finally, the pharmacokinetics and brain targeting index of MM-Lip-Rg3/PNS were investigated. Results: Our results indicated that MM-Lip-Rg3/PNS was spherical with a shell-core structure. MM-Lip-Rg3/PNS can avoid mononuclear phagocytosis, actively bind to inflammatory endothelial cells, and have the ability to cross the blood-brain barrier. Moreover, MM-Lip-Rg3/PNS could specifically target ischemic sites, even microglia, increase the cumulative number of drugs in the brain, improve the inflammatory environment of the brain, and reduce the infarct size. By comparing olfactory nerve-blocking rats with normal rats, it was found that there are direct and indirect pathways for nasal entry into the brain. Pharmacokinetics demonstrated that MM-Lip-Rg3/PNS exhibited stronger brain targeting and prolonged drug half-life. Conclusion: MM-Lip-Rg3/PNS might contribute to the accumulation of Rg3 and PNS in the ischemic brain area to improve treatment efficacy. This biomimetic nano-drug delivery system provides a new and promising strategy for the treatment of ischemic stroke. Keywords: macrophage-membrane coating, biomimetic liposome, brain targeting, ischemic stroke, intranasal delivery Graphical Ischemic stroke is mainly caused by cerebrovascular occlusion. It has the high incidence, mortality, and disability rate, which seriously affect human health and economic development. At present, the treatment of ischemic stroke mainly involves surgical intervention, which can clear intravascular thrombosis but still carries the risk of causing cerebral hemorrhage, 1 Alternatively, intravenous injection of recombinant tissue plasminogen activator (rt-PA), a widely recognized thrombolytic drug, is used, 2 However its treatment window is very narrow, and it may lead to neurotoxicity with significant toxic side effects. 3 In addition, recanalization of blood vessels can cause reperfusion injury, which increase oxidative stress and the release of pro-inflammatory factors, resulting in more serious damage. 4 Therefore, it is necessary to identify effective methods to reduce the damage caused by stroke and improve quality of life and survival rates. The treatment of central nervous system diseases through intranasal administration has garnered considerable attention. 5,6 Unlike oral administration, intranasal administration can bypass the first pass effect of the liver, thereby increasing drug delivery efficiency into the brain, 7,8 Meanwhile, compared to intravenous administration, intranasal administration is non-invasive and can alleviate patient pain, with safety and convenience. 9,10 Intranasal administration targets the brain through two pathways, Firstly, drugs can enter the brain directly and quickly through the trigeminal and olfactory nerve pathways. In addition, it can also enter the brain through an indirect pathway, that is, when the drug enters the nasal cavity, it enters the systemic circulation through the nasal respiratory mucosa and needs to cross the (blood-brain barrier) BBB before entering the brain. 5,11 To increase the delivery efficiency of drugs to the brain, it is necessary to explore a new type of nanomedicine. After intranasal administration, it can enter the brain through neural pathways. At the same time, it can also effectively cross the BBB, increase the amount of entry into the brain through indirect pathways -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology